Literature DB >> 21789136

What is the role of maintenance therapy in the treatment of non-small cell lung cancer?

Yixing Jiang1, Taofeek K Owonikoko, Suresh S Ramalingam, Fadlo R Khuri, Chandra P Belani.   

Abstract

Entities:  

Year:  2010        PMID： 21789136      PMCID： PMC3126019          DOI： 10.1177/1758834010368045

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


× No keyword cloud information.
  33 in total

1.  Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC).

Authors:  Josh J Carlson; Carolina Reyes; Nina Oestreicher; Deborah Lubeck; Scott D Ramsey; David L Veenstra
Journal:  Lung Cancer       Date:  2008-03-04       Impact factor: 5.705

2.  Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.

Authors:  Thomas Brodowicz; Maciej Krzakowski; Matjaz Zwitter; Valentina Tzekova; Rodryg Ramlau; Nicolae Ghilezan; Tudor Ciuleanu; Branka Cucevic; Kalman Gyurkovits; Ernst Ulsperger; Jacek Jassem; Mislav Grgic; Pinar Saip; Maria Szilasi; Christoph Wiltschke; Maria Wagnerova; Natalya Oskina; Victoria Soldatenkova; Christoph Zielinski; Miklos Wenczl
Journal:  Lung Cancer       Date:  2006-03-29       Impact factor: 5.705

3.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

4.  Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.

Authors:  Panos M Fidias; Shaker R Dakhil; Alan P Lyss; David M Loesch; David M Waterhouse; Jane L Bromund; Ruqin Chen; Maria Hristova-Kazmierski; Joseph Treat; Coleman K Obasaju; Martin Marciniak; John Gill; Joan H Schiller
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

5.  Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Authors:  Martin Reck; Joachim von Pawel; Petr Zatloukal; Rodryg Ramlau; Vera Gorbounova; Vera Hirsh; Natasha Leighl; Jörg Mezger; Venice Archer; Nicola Moore; Christian Manegold
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544

6.  Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer.

Authors:  Joon Oh Park; Sang-We Kim; Jin Seok Ahn; Cheolwon Suh; Jung Shin Lee; Joung Soon Jang; Eun Kyung Cho; Sung Hyun Yang; Jin-Hyuk Choi; Dae Seog Heo; Suk Young Park; Sang Won Shin; Myung Ju Ahn; Jong Seok Lee; Young Ho Yun; Jae-Won Lee; Keunchil Park
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

7.  The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.

Authors:  Giorgio Scagliotti; Nasser Hanna; Frank Fossella; Katherine Sugarman; Johannes Blatter; Patrick Peterson; Lorinda Simms; Frances A Shepherd
Journal:  Oncologist       Date:  2009-02-16

8.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

9.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

Authors:  Edward S Kim; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Yi-Long Wu; Long-Yun Li; Claire L Watkins; Mark V Sellers; Elizabeth S Lowe; Yan Sun; Mei-Lin Liao; Kell Osterlind; Martin Reck; Alison A Armour; Frances A Shepherd; Scott M Lippman; Jean-Yves Douillard
Journal:  Lancet       Date:  2008-11-22       Impact factor: 79.321

10.  Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.

Authors:  C von Plessen; B Bergman; O Andresen; R M Bremnes; S Sundstrom; M Gilleryd; R Stephens; J Vilsvik; U Aasebo; S Sorenson
Journal:  Br J Cancer       Date:  2006-10-03       Impact factor: 7.640
View more
  1 in total

1.  Anti-tumor enhancement of Fei-Liu-Ping ointment in combination with celecoxib via cyclooxygenase-2-mediated lung metastatic inflammatory microenvironment in Lewis lung carcinoma xenograft mouse model.

Authors:  Rui Liu; Honggang Zheng; Weidong Li; Qiujun Guo; Shulin He; Yoshiro Hirasaki; Wei Hou; Baojin Hua; Conghuang Li; Yanju Bao; Yebo Gao; Xin Qi; Yingxia Pei; Yun Zhang
Journal:  J Transl Med       Date:  2015-11-23       Impact factor: 5.531
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.